Health Beauty & Wellness Awards 2023

Health Beauty & Wellness Awards 2023 | 17 Our skin is one of our most defining characteristics. It’s the part of our body that we see the most, and sometimes even a small flaw can trigger a whole range of turbulent emotions. From depression to the destruction of self-confidence, skin conditions have the power to completely warp the way a person lives their life, and it may feel as though it’s just an inevitable part of having said condition. However, an award-winning biopharmaceutical company, Dermavant Sciences, is determined to help relieve skin problems so that patients can feel more comfortable in their skin. of topical prescription medication that is naturally identified, steroidfree, and only needs to be applied once a day,” the product has the potential to change the approach in how plaque psoriasis is currently treated. As a bonus, the product’s innovative formulation is non-greasy, cosmetically elegant, and absorbs quickly into the skin, and it does not contain any fragrance, petroleum jelly, para-aminobenzoic acid (PABA), parabens or gluten. After all, patients are at the core of everything Dermavant does, and the company is constantly looking for new solutions to age-old skin conditions that may have a myriad of positive health outcomes for patients. Dermavant believes that “skin is more than superficial – it’s where we live every moment of every day” and that “skin deserves more.” It’s this principle that is ultimately spearheading a belief that a change in the immuno-dermatology industry may shape the future of skin condition treatment in this space. * IQVIA National Prescription Audit (NPA) for the 3-month period ending 5/5/2023, reflecting estimates of real-world activity. All rights reserved. IMPORTANT SAFETY INFORMATION Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8-DERMAVANT (1-833762-8268). Please see full Prescribing Information. Trademarks are the property of Dermavant Sciences, GmbH. Contact: Angela Salerno-Robin Company: Dermavant Web Address: ince its establishment in 2015, Dermavant has relentlessly pursued its mission to make healthier skin a reality for the millions of people who struggle with chronic skin conditions. The company recognizes the significant impact that conditions like plaque psoriasis and atopic dermatitis can have on a person’s day-to-day life, including the toll these conditions can take on emotional health, and has vowed to develop treatments that “doctors want to prescribe, and patients want to use.” While pursuing this mission, Dermavant quickly become an industry leader in the plaque psoriasis topical treatment space. Within two months of receiving Food and Drug Administration (FDA) approval in May 2022, the company’s first in class, specialised plaque psoriasis treatment became the #1 prescribed branded topical treatment for adults with plaque psoriasis.* By delivering ground-breaking science where patients need it — their skin — Dermavant strives to help these patients find relief from their condition. The company isn’t afraid of the trials and tribulations of drug discovery, and its passion and entrepreneurial spirit resulted in the first new class of topical medication approved for plaque psoriasis in more than 25 years. Plaque psoriasis is a common, chronic autoimmune disease that leaves patches of an individual’s skin looking scaly and aggravated. Prior to the approval of VTAMA® (tapinarof) cream, 1%, there were a limited number of topical treatments on the market for treating the condition long-term. Typically, patients start with topical steroids; however, many can be challenging to use, as some are limited by where they can be used on the body and for how long and how often they can be used — creating demand for a novel, steroid-free topical treatment that could be used even on sensitive skin areas. This is what inspired Dermavant to advance VTAMA cream for healthcare providers and the patients they serve. Acting as “an entirely new class S Best Biopharmaceutical Company 2023